Petrovax Pharm has successfully fulfilled the government contracts under Russia's National Immunisation Schedule. In 2015, Petrovax produced over 19 m Grippol® Plus vaccine doses, up 30% y-o-y. In October, the Company became the first flu vaccine manufacturer to complete the shipments of 13.8 m Grippol® Plus doses across Russia to prevent flu in children and pregnant women. For the first time in its history, in 2015, Petrovax Pharm exported over 3.5 m doses of Grippol® Plus to Belarus, becoming the only supplier under the Republic's National Immunisation Schedule to provide vaccine for all social groups and cover 40% of the Belarusian population. On top of that, under the immunisation programme the Company shipped flu vaccine to Kyrgyzstan, Kazakhstan and Iran.
From November to December 2015, the Company supplied 3.7 m doses of Prevenar 13®, a 13-valent pneumococcal conjugate vaccine used to treat infants under one year, shipped under the government contracts (up 10% y-o-y). In August 2015, the Russian Ministry of Health issued an authorisation for the full-cycle production of Prevenar 13®, which came as a final stage in the implementation of a strategic import substitution project delivered jointly with Pfizer. The total output of Prevenar 13® in 2015 went up by 20% y-o-y.
"The production of immunobiological medicines and timely fulfilment of government procurement contracts under the National Immunisation Schedule are a key area of our business which receives a lot of attention from the management. Each year, Petrovax Pharm launches and implements projects to develop and manufacture new medicines meeting the needs of the healthcare system and patients. We are proud to have been supplying our medicines to the Russian and international consumers for years now. Their high quality has been confirmed by the long track record of clinical use," said Elena Arkhangelskaya, President of NPO Petrovax Pharm. "The 20 years of experience in developing and manufacturing immunobiological medicines make us feel confident about the Company's strong development potential."All news